Salvage of local recurrence after primary thermal ablation for small renal masses.

Abstract:

:The management of renal tumors has evolved rapidly over the last two decades, with the ascendance of nephron-sparing surgery (NSS), largely spurred by the increased incidental detection of small renal masses (SRMs) and evidence that preservation of renal parenchyma reduces the risk of chronic kidney disease. The field of NSS itself has advanced beyond the standard of open partial nephrectomy, with the application of minimally invasive techniques, such as laparoscopy and thermal ablation. Energy-based ablative therapies, which include cryoablation and radiofrequency ablation, are associated with reduced morbidity and represent a nascent but promising alternative to surgical extirpation in the treatment of SRMs. However, thermal ablation is associated with a higher rate of local tumor recurrence when compared with surgical excision, indicating that salvage therapy will be a necessity for some patients. With recent studies indicating that surgical excision of previously ablated kidneys can be complicated by significant fibrosis, clinicians who advocate thermal ablation must be cognizant of the sequelae of this treatment modality and versed on the potential difficulties associated with salvage surgery. We provide, herein, an assessment of the efficacy and limitations of primary thermal ablation and strategies for salvage treatment of local recurrence in this growing patient population.

authors

Nguyen CT,Campbell SC

doi

10.1586/14737140.8.12.1899

subject

Has Abstract

pub_date

2008-12-01 00:00:00

pages

1899-905

issue

12

eissn

1473-7140

issn

1744-8328

journal_volume

8

pub_type

杂志文章,评审
  • Darbepoetin alfa for the treatment of cancer-related anemia: an update.

    abstract::Anemia is a common and potentially debilitating complication of cancer. Darbepoetin alfa (Aranesp, Amgen) has been in routine clinical use for the treatment of chemotherapy-induced anemia since 2002. The extended half-life of darbepoetin alfa permits less frequent and consequently more flexible dosing than other eryth...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.5.735

    authors: Pirker R

    更新日期:2004-10-01 00:00:00

  • Fertility preservation in women with CNS tumors.

    abstract:INTRODUCTION:Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard s...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1316195

    authors: Tosoni A,Balestrini D,Brandes AA

    更新日期:2017-05-01 00:00:00

  • CyberKnife robotic radiosurgery system for tumor treatment.

    abstract::Defined by its high level of accuracy and rapid radiation dose fall-off, radiosurgery has emerged as an effective radiation technique over the past few decades. Although it was once limited to conditions of the brain, head and neck regions, technological advances in computing and imaging have allowed the application o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.11.1507

    authors: Hara W,Soltys SG,Gibbs IC

    更新日期:2007-11-01 00:00:00

  • Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.

    abstract::With the introduction of orally-active, potent and selective third-generation aromatase inhibitors and inactivators--anastrozole, letrozole and exemestane--approaches to the treatment of advanced breast cancer are undergoing re-evaluation. In advanced breast cancer, aromatase inhibitors and inactivators are likely to ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.3.267

    authors: Dixon JM

    更新日期:2002-06-01 00:00:00

  • Specific challenges in the management of subungual melanoma.

    abstract::Subungual melanoma (SUM) is infrequent in the general population, accounting for 0.7-3.5% of all cutaneous melanomas. SUM absolute incidence is similar among different racial groups; however, the relative proportion among overall cutaneous melanoma cases within each population varies in relation to the frequency of su...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.216

    authors: De Giorgi V,Saggini A,Grazzini M,Gori A,Rossari S,Scarfì F,Verdelli A,Chimenti S,Lotti T,Massi D

    更新日期:2011-05-01 00:00:00

  • Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.

    abstract::Nonseminomatous germ cell tumors of the testicle are highly treatable and curable. The evolution of cancer control for this disease has demonstrated an effective integration of medical and surgical approaches over the last 30 years. Current emphasis in the therapy of nonseminomatous germ cell tumors focuses on minimiz...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.1.75

    authors: Yoon GH,Stein JP,Skinner DG

    更新日期:2005-02-01 00:00:00

  • miRNA as markers for the diagnostic screening of colon cancer.

    abstract::Early screening for colon cancer (CC) allows for early stage diagnosis of the malignancy and potentially reduces disease mortality as the cancer is most likely curable at its earliest stages. Early detection would be desirable if accurate, practical and cost-effective diagnostic measures for this cancer were available...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.869479

    authors: Ahmed FE

    更新日期:2014-04-01 00:00:00

  • The role of combination chemo-immunotherapy in advanced non-small cell lung cancer.

    abstract::Introduction: Even with the currently recommended chemotherapeutic and immunotherapeutic treatment, the five year survival rate for advanced nonsquamous and squamous NSCLC without oncogenic drivers remains poor. However, several different chemo-immunotherapy combinations are presently being investigated - with favorab...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1631800

    authors: Rocco D,Della Gravara L,Battiloro C,Gridelli C

    更新日期:2019-07-01 00:00:00

  • Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.

    abstract::Anemia is a frequent problem in cancer patients, especially in those treated with chemotherapy, and has an important negative impact on quality of life. Red blood cell transfusions provide clear but rather temporary comfort. The development of erythropoietic stimulating agents (ESAs) led to a more durable anemia treat...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.10.1347

    authors: Vansteenkiste J,Wauters I

    更新日期:2007-10-01 00:00:00

  • Role and value of diffusion-weighted MRI in the radiotherapeutic management of head and neck cancer.

    abstract::With the association of concurrent chemotherapy, the widespread implementation of altered fractionation schedules and the use of more conformal radiotherapy techniques, the locoregional management of patients with squamous cell carcinoma of the head and neck region (HNSCC) has greatly improved over the last decades. H...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.121

    authors: Lambrecht M,Dirix P,Vandecaveye V,De Keyzer F,Hermans R,Nuyts S

    更新日期:2010-09-01 00:00:00

  • Colon and rectal cancer after renal transplantation.

    abstract::Increased cancer risk after renal transplantation is believed to be a consequence of continuous immunosuppression. However, the risk of colorectal cancer (CRC) after renal transplantation is controversial and has received limited study. Accumulating evidence suggests that colon and rectal cancers have different charac...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.8.1339

    authors: Kan M,Gill JS,Wiseman SM

    更新日期:2008-08-01 00:00:00

  • Emerging application of stereotactic body radiation therapy for gynecologic malignancies.

    abstract::Stereotactic body radiation therapy (SBRT) involves delivery of image-guided, ablative radiation doses to planning treatment volume(s) using sophisticated dosimetric planning and target localization. Early on, clinical investigators pursued SBRT for the treatment of early stage non-small-cell lung cancer, lung and liv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.81

    authors: Mayr NA,Huang Z,Sohn JW,Lo SS,Teh BS,Lu JJ,Grecula JC,Kunos C

    更新日期:2011-07-01 00:00:00

  • Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.

    abstract:INTRODUCTION:Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until in...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1785289

    authors: Manceau C,Mourey L,Pouessel D,Ploussard G

    更新日期:2020-08-01 00:00:00

  • Highlights of the 2nd European Lung Cancer Conference.

    abstract::The Second European Lung Cancer Conference was held in Geneva, Switzerland from 28 April to 1 May 2010, under the cosponsorship of the International Association for the Study of Lung Cancer and the European Society for Medical Oncology. The main topics included: tobacco control, which represents a crucial challenge fo...

    journal_title:Expert review of anticancer therapy

    pub_type:

    doi:10.1586/era.10.93

    authors: Girard N,Mornex F

    更新日期:2010-07-01 00:00:00

  • Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.

    abstract::Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer se...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.4.489

    authors: Braun MS,Quirke P,Seymour MT

    更新日期:2007-04-01 00:00:00

  • Neoadjuvant chemotherapy in invasive bladder cancer.

    abstract::The role of neoadjuvant chemotherapy in muscle-invasive bladder cancer has been clarified by recent randomized studies and meta-analyses, which all showed that cisplatin-based, combination chemotherapy offers a significant survival advantage. Preoperative chemotherapy results in downstaging in a significant percentage...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.6.993

    authors: Bamias A,Dimopoulos MA

    更新日期:2005-12-01 00:00:00

  • The multidisciplinary management of giant cell tumor of bone.

    abstract::Giant cell tumor of bone is a locally aggressive lesion with a predilection for local recurrence, and in a small proportion of patients, metastatic disease can develop. Surgery is the mainstay of management for extremity-based lesions. For tumors located in challenging anatomical locations such as the sacrum and spine...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.901891

    authors: Ng VY,Davidson DJ,Kim EY,Pollack SM,Conrad Iii EU,Jones RL

    更新日期:2014-07-01 00:00:00

  • Towards personalized therapy for patients with glioblastoma.

    abstract::Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12-15 months. Currently, several clinical trials of dose-dense temozolomide regimen or molecular-targ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.103

    authors: Shirai K,Chakravarti A

    更新日期:2011-12-01 00:00:00

  • Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review.

    abstract::Neurocognitive function (NCF) impairment is an important component of primary and metastatic brain tumors and their therapeutic interventions. As a result, modern clinical trials of cranial irradiation for adult cancer patients have incorporated NCF testing as a primary or secondary end point. In doing so, these clini...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.34

    authors: Caine C,Mehta MP,Laack NN,Gondi V

    更新日期:2012-05-01 00:00:00

  • The influence of pH and hypoxia on tumor metastasis.

    abstract::Rapid malignant proliferation, prior to effective tumor neoangiogenesis, creates a microenvironment around solid cancers, which is predominantly hypoxic and characterized by a high interstitial fluid pressure. Presumably as an adaptive response, tumor cells favor metabolic activity with apparently inefficient energy o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.843455

    authors: Abaza M,Luqmani YA

    更新日期:2013-10-01 00:00:00

  • Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.

    abstract:INTRODUCTION:The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worseni...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1770601

    authors: Donini M,Buti S,Massari F,Mollica V,Rizzo A,Montironi R,Bersanelli M,Santoni M

    更新日期:2020-06-01 00:00:00

  • Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments.

    abstract::Small cell carcinoma of the urinary bladder (SCCUB) is a rare and aggressive disease. To date, no standard treatment has been proposed due to the lack of prospective studies resulting from the rarity of this disease. Recently published studies of relatively large patient cohorts, however, have shed some light on the m...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.851605

    authors: Koga F,Yokoyama M,Fukushima H

    更新日期:2013-11-01 00:00:00

  • Nivolumab for the treatment of colorectal cancer.

    abstract:INTRODUCTION:Despite a variety of therapies for advanced metastatic colorectal cancer being available, the outcomes in this malignancy remain suboptimal. Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had disappointing results when used broadly...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1480942

    authors: Smith KM,Desai J

    更新日期:2018-07-01 00:00:00

  • Statistical approaches for evaluating body composition markers in clinical cancer research.

    abstract:INTRODUCTION:The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review st...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1298446

    authors: Bayar MA,Antoun S,Lanoy E

    更新日期:2017-04-01 00:00:00

  • Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.

    abstract::This review summarizes the safety of sorafenib, an oral multikinase inhibitor, focusing on the randomized, placebo-controlled, Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) in renal cell carcinoma, which formed the basis of the approval of sorafenib. Similar to other targeted agents, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1193

    authors: Hutson TE

    更新日期:2007-09-01 00:00:00

  • Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.

    abstract:INTRODUCTION:The success of the immune checkpoint inhibitors in melanoma has reinvigorated the field of immunotherapy. Immune checkpoint inhibitors are now the standard of care in multiple cancer types including lung cancer, head and neck cancer, urothelial cancer and renal cell cancer. The field of immunotherapy is cu...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1341315

    authors: O'reilly A,Larkin J

    更新日期:2017-07-01 00:00:00

  • Role of chemotherapy in breast cancer.

    abstract::Breast cancer represents a major health problem, with more than a million new cases and 370,000 deaths worldwide yearly. Options and understanding of how to use cytotoxic chemotherapy in both advanced and early stage breast cancer have made substantial progress in the past 10 years, with numerous landmark studies iden...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.6.1095

    authors: Hussain SA,Palmer DH,Stevens A,Spooner D,Poole CJ,Rea DW

    更新日期:2005-12-01 00:00:00

  • Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.

    abstract::According to computed tomography image analysis, skeletal muscle (SM) and adipose tissue areas vary widely in patients with the same body mass index or the same body surface area. Body composition variables such as SM mass, SM density and subcutaneous and visceral adipose tissue have shown value as potential independe...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.866040

    authors: Antoun S,Lanoy E,Albiges-Sauvin L,Escudier B

    更新日期:2014-03-01 00:00:00

  • Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.

    abstract::Tumors of the CNS frequently have devastating consequences in terms of cognitive and motor function, personality and mortality. Despite decades of work, current therapies have done little to alter the course of these deadly diseases. The discovery that chaperones/heat-shock proteins play an important role in tumor bio...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.5.679

    authors: Graner MW,Bigner DD

    更新日期:2006-05-01 00:00:00

  • Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

    abstract::Until now, no effective systemic treatment options have been available for patients with unresectable advanced hepatocellular carcinoma (HCC). In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/era.09.41

    authors: Rimassa L,Santoro A

    更新日期:2009-06-01 00:00:00